Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)

计划入组 106 人 · 首次发布于 2017 年 6 月 22 日

n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation

计划入组 199 人 · 首次发布于 2010 年 9 月 10 日

ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic

计划入组 44 人 · 首次发布于 2020 年 4 月 1 日

RAS-F3

RAS-001

RAS-111

Erasca

United States

Revolution Medicines, Inc.

United States

Ikena Oncology

United States

Racial Heterogeneity Unlikely to Affect RAS Blocker Benefits, Re-Analysis Suggests

Beta-Blockers Offer New Hope for Huntington's Disease Patients

UK Clinical Trial Aims to Resolve Debate on Puberty Blockers for Gender Dysphoria